In addition to pembrolizumab, the PD-L1 inhibitor atezolizumab is also evaluated in combination with carboplatin plus paclitaxel in a phase III study with or without the addition of bevacizumab in primary stage IV NSCLC (IMpower150) (NCT02366143) (Table 2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.